Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases

TL;DR

This study shows that portosystemic shunts and portal vein stents can effectively manage portal hypertension in patients with hematological diseases.

Contribution

The study provides evidence for the effectiveness of TIPS and stents in treating portal hypertension caused by hematological conditions.

Findings

Eight out of 11 patients experienced resolution of portal hypertension after treatment.

Rebleeding occurred in three patients due to incomplete resolution or TIPS closure.

The median follow-up period was 420 days.

Abstract

Introduction: Patients with hematological diseases experience complications related to portal hypertension, including life-threatening complications such as variceal bleeding.

Methods: We analyzed the prognosis of patients with hematological diseases and portal hypertension treated with transjugular intrahepatic portosystemic shunts (TIPS) or portal vein stents. We retrospectively assessed patients with hematological diseases and portal hypertension who had variceal bleeding. We evaluated the characteristics and prognosis of the enrolled patients. A total of 11 patients with hematological diseases who underwent TIPS, or portal vein stenting, were evaluated.

Results: The median follow-up period was 420 days. Of the 11 patients, eight showed resolution of portal hypertension and its complications following TIPS, or stent insertion. One patient experienced rebleeding due to incomplete resolution of portal hypertension, and two other patients also experienced rebleeding because they underwent TIPS closure or revision due to repetitive hepatic encephalopathy.

Conclusion: Portosystemic shunt and stent installation are effective treatment options for portal hypertension due to hematological diseases.

Figures